Sequential Metronidazole-Furazolidone or Clarithromycin-Furazolidone Compared to Clarithromycin-Based Quadruple Regimens for the Eradication of Helicobacter pylori in Peptic Ulcer Disease: A Double-Blind Randomized Controlled Trial

Helicobacter

Volumn 15, Issue 6, 2010, Pages 497-504

  Riahizadeh, Saghi ^a   Malekzadeh, Reza ^a   Agah, Shahram ^b   Zendehdel, Nasrin ^a   Sotoudehmanesh, Rasoul ^a   Ebrahimi Dariani, Naser ^a   Pourshams, Akram ^a   Vahedi, Homayoon ^a   Mikaeli, Javad ^a   Khatibian, Morteza ^a   Massarrat, Sadegh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Clarithromycin; Eradication; Furazolidone; H. pylori

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; CLARITHROMYCIN; FURAZOLIDONE; METRONIDAZOLE; OMEPRAZOLE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BLOATING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG FEVER; DUODENITIS; ERADICATION THERAPY; FEMALE; FLUSHING; HEADACHE; HELICOBACTER PYLORI; HUMAN; MALE; NAUSEA; NONHUMAN; PEPTIC ULCER; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TASTE; UREA BREATH TEST; VOMITING; WEAKNESS; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PEPTIC ULCER; YOUNG ADULT;

HELICOBACTER PYLORI;

EID: 78349271200     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2010.00798.x     Document Type: Article

References (55)

1. Paoluzi P, Iacopini F, Crispino P, Nardi F, Bella A, Rivera M, Rossi P, Gurnari M, Caracciolo F, Zippi M, Pica R. 2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006;11:562-8.
2. Calvet X, Ducons J, Bujanda L, Bory F, Montserrat A, Gisbert JP. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005;100:1696-701.
3. Rokkas T, Sechopoulos P, Robotis I, Margantinis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen. Am J Gastroenterol 2009;104:21-5.
4. Altintas E, Sezgin O, Ulu O, Aydin O, Camdeviren H. Maastricht II treatment scheme and efficacy of different proton pump inhibitors in eradicating Helicobacter pylori. World J Gastroenterol 2004;10:1656-8.
5. Gumurdulu Y, Serin E, Ozer B, Kayaselcuk F, Ozsahin K, Cosar AM, Gursoy M, Gur G, Yilmaz U, Boyacioglu S. Low eradication rate of Helicobacter pylori with triple 7-14 days and quadruple therapy in Turkey. World J Gastroenterol 2004;10:668-71.
6. Gisbert JP, Pajares JM. Review article: Helicobacter pylori"rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
7. Parente F, Cucino C, Bianchi-Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003;35:523-8.
8. Mendonça S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J Jr. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and furazolidone in Brazil. Helicobacter 2000;5:79-83.
9. Midolo PD, Korman MG, Turnidge JD, Lambert JR. Helicobacter pylori resistance to tetracycline. Lancet 1996;347:1194-5.
10. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, Graham DY. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001;45:306-8.
11. Zheng ZT, Wang ZY, Chu YX, Li YN, Li QF, Lin SR, Xu ZM. Double-blind short-term trial of furazolidone in peptic ulcer. Lancet 1985;1:1048-9.
12. Zhao HY, Li GZ, Guo JD, Yan Z, Sun SW, Li LS, Duan YM, Yue FZ. Furazolidone in peptic ulcer. Lancet 1985;2:276-7.
13. Safaralizadeh R, Siavoshi F, Malekzadeh R, Akbari MR, Derakhshan MH, Sohrabi MR, Massarrat S. Antimicrobial effectiveness of furazolidone against metronidazole. East Mediterr Health J 2006;12:286-93.
14. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J Gastroenterol 2009;15:860-4.
15. Khatibian M, Ajvadi Y, Nasseri-Moghaddam S, Ebrahimi-Dariani N, Vahedi H, Zendehdel N, Sotoudehmanesh R, Agah S, Mikaeli J, Pourshams A, Ali-Asgari A, et al. Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. Arch Iran Med 2007;10:161-7.
16. Felga GE, Silva FM, Barbuti RC, Navarro-Rodriguez T, Zaterka S, Eisig JN. Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease. World J Gastroenterol 2008;14:6224-7.
17. Moher D, Schulz KF, Altman DG; CONSORT GROUP (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001;17:134.
18. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
19. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-25.
20. Fock KM. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
21. Vilaichone RK, Mahachai V, Graham DY. Helicobacter pylori diagnosis and management. Gastroenterol Clin North Am 2006;35:229-47.
22. Megraud F. Strategies to treat patients with antibiotic resistant Helicobacter pylori. Int J Antimicrob Agents 2000;16:507-9.
23. Peitz U, Sulliga M, Wolle K, Leodolter A, Von Arnim U, Kahl S, Stolte M, Börsch G, Labenz J, Malfertheiner P. High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two-second-line therapies in a randomized study. Aliment Pharmacol Ther 2002;16:315-24.
24. Chinese Helicobacter pylori Research Group, Chinese Society of Gastroenterology. Prevalence of Helicobacter pylori resistance to antibiotics and its influence on the treatment outcome in China: a multicenter clinical study. Weichang Bingxue 2007;12:525-30.
25. Eisig JN, Silva FM, Rodriguez TN, Hashimoto CL, Barbuti RC. A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease. Clinics (Sao Paulo) 2005;60:485-8.
26. Bazzoli F. My approach to Helicobacter pylori eradication. Eur Gastroenterol Hepatol 1999;11(Suppl. 1):S37-41.
27. Roghani HS, Massarrat S, Pahlewanzadeh MR, Dashti M. Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains. Eur J Gastroentrol Hepatol 1999;11:709-12.
28. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23:35-44.
29. Van der Poorten D, Katelaris PH. The effectiveness of rifabutin triple therapy for patients with difficult-to-eradicate Helicobacter pylori in clinical practice. Aliment Pharmacol Ther 2007;26:1537-42.
30. Al tamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl 1989;169:70-80.
31. Sotoudehmanesh R, Malekzadeh R, Vahedi H, Dariani NE, Asgari AA, Massarrat S. Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen. Digestion 2001;64:222-5.
32. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, Sotodehmanesh R, Haghpanah B, Bahrami H. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit 2003;9:105-9.
33. Treiber G, Ammon S, Malfertheiner P, Klotz U. Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures. Helicobacter 2002;7:225-31.
34. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002;16:1277-82.
35. Wong WM, Wong BC, Lu H, Gu Q, Yin Y, Wang WH, Fung FM, Lai KC, Xia HH, Xiao SD, Lam SK. One-week omeprazole, furazolidone, andamoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002;16:793-8.
36. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari M, Massarrat S. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000;14:299-303.
37. Frota LC, Da Cunha Mdo P, Luz CR, De Araujo-Filho AH, Frota LA, Braga LL. Helicobacter pylori eradication using tetracycline and furazolidone versus amoxicillin and azithromycin in lansoprazole-based triple therapy: an open randomized clinical trial. Arq Gastroenterol 2005;42:111-5.
38. Araujo-Castillo R, Pinto-Valdivia JL, Ramirez D, CokGarcia J, Bussalleu-Rivera A. New ultrashort scheme for Helicobacter pylori infection eradication using tetracyline, furazolidone, and colloidal bismuth subcitrate in dyspeptic patients with or without peptic ulceration in the National Hospital Cayetano Heredia. Rev Gastroenterol Peru 2005;25:23-41.
39. Mansour-Ghanaei F, Fallah MS, Shafaghi A. Eradication of Helicobacter pylori induodenal ulcer disease: tetracycline and furazolidone vs. metronidazole and amoxicillin in omeprazole-based triple therapy. Med Sci Monit 2002;8:27-30.
40. Lu H, Zhang DZ, Hu PJ, Li ZS, Lu XH, Fang XC, Xiao SD. One-week regimens containing ranitidine, bismuth citrate, furazolidone, and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicenter, randomized, double-blind study. Aliment Pharmacol Ther 2001;15:1975-9.
41. Liu WZ, Xiao SD, Hu PJ, Lu H, Cui Y, Tytgat GN. A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin, and famotidine. Aliment Pharmacol Ther 2000;14:1519-22.
42. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000;14:211-5.
43. Xiao SD, Liu WZ, Hu PJ, Xia DH, Tytgat GN. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone, and clarithromycin triple therapy for 1 week. Aliment Pharmacol Ther 1999;13:311-5.
44. Dani R, Queiroz DM, Dias MG, Franco JM, Magalhaes LC, Mendes GS, Moreira LS, De Castro LP, Toppa NH, Rocha GA, Cabral MM. Omeprazole, clarithromycin, and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer. Aliment Pharmacol Ther 1999;13:1647-52.
45. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther. 2005; 1; 21(1): 91-6.
46. Sotudehmanesh R, Malekzadeh R, Fazel A, Massarrat S, Ziad-Alizadeh B, Eshraghian MR. A randomized controlled comparison of three quadruple therapy regimens in a population with low Helicobacter pylori eradication rates. J Gastroenterol Hepatol 2001;16:264-8.
47. Silva FM, Eisig JN, Chehter EZ, Silva JJ, Laudanna AA. Omeprazole, furazolidone, and tetracycline: an eradication treatment for resistant H. pylori in Brazilian patients with peptic ulcer disease. Rev Hosp Clin Fac Med Sao Paulo 2002;57:205-8.
48. Eisig JN, Silva FM, Barbuti RC, Rodriguez TN, Malfertheiner P, Moraes Filho JP, Zaterka S. Efficacy of a 7-day course of furazolidone, levofloxacin, and lansoprazole after failed Helicobacter pylori eradication. BMC Gastroenterol 2009;9:38-42.
49. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, Massarrat S. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001;15:411-6.
50. Salman-Roghani H, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol 2003;18:778-82.
51. Siavoshi F, Pourkhajeh AH, Merat SH, Asl-Soleimani H, Heydarian E, Khatibian M, Malekzadeh R. Susceptibility of various strains of Helicobacter pylori to selected agents. Arch Iran Med 2000;2:60-3.
52. Siavoshi F, Saniee P, Latifi-Navid S, Massarrat S, Sheykholeslami A. Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline-comparison of three 3-year studies. Arch Iran Med 2010;13:177-87.
53. Malekzadeh R, Mohamadnejad M, Siavoshi F, Massarrat S. Treatment of Helicobacter pylori infection in Iran: low efficacy of recommended western regimens. Arch Iran Med 2004;7:1-8.
54. Tatsuta M, Iishi H, Baba M, Taniguchi H. Attenuating effect of the monoamine oxidase inhibitor furazolidone on the anti-carcinogenetic effect of cysteamine on gastric carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in Wistar rats. Int J Cancer 1991;48:605-8.
55. Auro A, Sumano H, Ocampo L, Barragán A. Evaluation of the carcinogenic effects of furazolidone and its metabolites in two fish species. Pharmacogenomics J 2004;4:24-8.